7th Eurasian Hematology Oncology Summit
2020 Update on High-Risk MDS: Does Aza Improve OS/ORR? How to Minimize Toxicity? Is Cytarabine Still the SoC? Are Novel Agents Promising?
By
7th Eurasian Hematology Oncology Summit
FEATURING
Moshe Mittelman
By
7th Eurasian Hematology Oncology Summit
FEATURING
Moshe Mittelman
Login to view comments.
Click here to Login
